Anteris Technologies Global Corp. (NASDAQ:AVR) shares jumped 52.17% in after-hours trading on Tuesday, reaching $8.75, following the announcement of a major capital raise.According to Benzinga Pro data, AVR closed the regular session at $5.75, up 12.52%.$200 Million Public Offering AnnouncedThe Brisbane-based structural heart company announced plans for a $200 million underwritten public offering of common stock, according to a Monday press release. Underwriters were granted a 30-day option to purchase an a ...

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].